Impact of immunosuppression on the incidence of early subclinical renal allograft rejection: Implications for protocol biopsy policy

Transplant International

Volumn 22, Issue 8, 2009, Pages 831-836

  Roberts, Ian S D ^a   Stratopoulos, Charalabos ^b   Zilvetti, Miguel ^b   Reddy, Srikanth ^b   Friend, Peter J ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Protocol biopsies; Renal transplantation; Subclinical rejection

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; POLICY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BIOPSY; CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; POSTOPERATIVE CARE; PREDNISOLONE; RECOMBINANT FUSION PROTEINS; TACROLIMUS;

EID: 67651159186     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00878.x     Document Type: Article

References (26)

1. Rush DN, Jeffery JR, Gough J. Sequential protocol biopsies in renal transplant patients. Transplantation 1995 59 : 511.
2. Seron D, Moreso F, Bover J, et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997 51 : 310.
3. Rush DN, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998 9 : 2129.
4. Jain S, Curwood V, Kazi J, White SA, Furness PN, Nicholson ML. Acute rejection in protocol renal transplant biopsies: institutional variations. Transplant Proc 2000 32 : 616.
5. Jain S, Curwood V, White SA, Furness PN, Nicholson ML. Sub-clinical acute rejection detected using protocol biopsies in patients with delayed graft function. Transpl Int 2000 13 (Suppl. 1 S52.
6. Nankivell BJ, Fenton-Lee CA, Kuypers DRJ, et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001 71 : 515.
7. Shapiro R, Randhawa P, Jordan ML, et al. An analysis of early renal transplant protocol biopsies: the high incidence of subclinical tubulitis. Am J Transplant 2001 1 : 47.
8. Gloor JM, Cohen AJ, Lager DJ, et al. Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 2002 73 : 1965.
9. Roberts ISD, Reddy S, Russell C, et al. Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation. Transplantation 2004 77 : 1194.
10. Nankivell BJ, Borrows RJ, Fung CL, et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004 78 : 242.
11. Moreso F, Seron D, Carrera M, et al. Baseline immunosuppression is associated with histological findings in early protocol biopsies. Transplantation 2004 78 : 1064.
12. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 55 : 713.
13. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007 7 : 2538.
14. Scholten EM, Rowshani AT, Cremers S, et al. Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function. J Am Soc Nephrol 2006 17 : 2622.
15. Rowshani AT, Scholten EM, Bemelman F, et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol 2006 17 : 305.
16. Jurewicz WA. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report. Transplant Proc 1993 31 (Suppl. 7A 64S.
17. Nankivell BJ, Borrows RJ, Fung CL-S, O'Connell PJ, Allen RDM, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003 349 : 2326.
18. Choi BS, Shin MJ, Shin SJ, et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation; ten-year experience at a single center. Am J Transplant 2005 5 : 1354.
19. Hymes LC, Greenbaum L, Amaral SG, Warshaw BL. Surveillance renal transplant biopsies and subclinical rejection at three months post-transplant in pediatric recipients. Pediatr Transplant 2007 11 : 536.
20. Nickerson P, Jeffery JR, Gough J, et al. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: a pilot study. J Am Soc Nephrol 1999 10 : 1801.
21. Hoffmann FC, Hale DA, Kleiner DE, et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005 5 : 573.
22. Woodroffe R, Yao GL, Meads C, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 2005 9 : 1.
23. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004 136 : 754.
24. Seron D, Moreso F, Ramon JM, et al. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 2000 69 : 1849.
25. Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA. Molecular and structural consequences of early renal allograft injury. Kidney Int 2002 61 : 686.
26. Yilmaz S, Tomlanovich S, Mathew T, et al. Protocol core needle biopsy and histologic chronic allograft damage index (CADI) as surrogate end point for long-term graft survival in mulitcenter studies. J Am Soc Nephrol 2003 14 : 773.